Biontech Se Sponsored Adr Stock News

Pfizer and BioNTech have applied to have their coronavirus vaccine approved by the South African Health Regulatory Products Authority for use as a booster.

Could these biotech stocks be poised for long-term gains?

Jens Spahn rushes out extra doses of BioNTech/Pfizer shot, calls Moderna the ''Rolls Royce'' of vaccines.

Tumour Vaccine Market analysis report puts across the idea of a high-level analysis of major market segments and identification of opportunities. This information not only aids businesses in taking sound and proficient decisions but also helps decide the advertising, promotion,

Creative Financial Designs Inc. ADV bought a new stake in BioNTech SE (NASDAQ:BNTX) in the third quarter, HoldingsChannel.com reports. The firm bought 100 shares of the companys stock, valued at approximately $27,000. Several other institutional investors have also made changes to their positions in BNTX. Firestone Capital Management bought a new stake in shares of []

The booster dose of Pfizer (PFE) and BioNTechs (BNTX) COVID-19 vaccine has received extended authorization for emergency use from the U.S. The post Pfizer-BioNTechs COVID-19 Booster Gets FDA Approval for People 18 & Above appeared first on Smarter Analyst .

Pfizer Inc. and BioNTech SE announced on Monday the results of the phase 3 trial of their COVID-19 vaccine in adolescents between the ages of 12 and 15. The trial included 2,228 participants and showe

Neoantigen Vaccine Market is an outstanding market research report that conducts industry analysis on products, markets, companies, industries, and many countries worldwide. When it is about guessing general market conditions, the growth prospects in the market, likely restrictions, significant industry

Pfizer-BioNTech vaccine demonstrated 100% efficacy against COVID-19 in longer-term analysis, with no serious safety concerns identified Data will support planned submissions for full regulatory app

NEW YORK and MAINZ, GERMANY, November 22, 2021 Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in individuals 12 through 15 years of age. The updated findings from the companies pivotal Phase 3 trial show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-µg per dose) was 100% effective against COVID-19, measured seven days through over four months after the second dose.

The FDA authorizes booster doses of COVID-19 vaccines of PFE/BNTX and MRNA for use in all adults irrespective of the risk of exposure to coronavirus.

Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have announced topline results from a longer-term analysis of the safety and efficacy of their COVID-19 Vaccine in individuals 12 through 15

These awesome stocks don't need COVID-19 to beat the market.

Pfizer Inc. PFE, -1.19% and BioNTech SE BNTX, +5.73% said Monday that topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in people 12 through 15 show that

Two of the main Western producers of COVID-19 vaccines plan to open manufacturing plants in Africa. Moderna is to invest up to USD500m for the construction of a state-of-the-art facility in an unspecified location within two to four years. Over time the plan is to produce 500 million vaccines per year. BioNTech, the German partner []